1. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
- Author
-
Heirali AA, Acosta N, Storey DG, Workentine ML, Somayaji R, Laforest-Lapointe I, Leung W, Quon BS, Berthiaume Y, Rabin HR, Waddell BJ, Rossi L, Surette MG, and Parkins MD
- Subjects
- Administration, Inhalation, Adult, Anti-Bacterial Agents administration & dosage, Female, Humans, Male, Outcome Assessment, Health Care methods, Patient Outcome Assessment, Respiratory Function Tests, Sputum microbiology, Aztreonam administration & dosage, Cystic Fibrosis drug therapy, Cystic Fibrosis physiopathology, Cystic Fibrosis psychology, Cystic Fibrosis therapy, Diagnostic Self Evaluation, Lung microbiology, Lung physiopathology, Microbiota drug effects, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa isolation & purification
- Abstract
Background: To improve clinical outcomes, cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections are prescribed inhaled anti-pseudomonal antibiotics. Although, a diverse microbial community exists within CF airways, little is known about how the CF microbiota influences patient outcomes. We hypothesized that organisms within the CF microbiota are affected by inhaled-antibiotics and baseline microbiome may be used to predict therapeutic response., Methods: Adults with chronic P. aeruginosa infection from four clinics were observed during a single 28-day on/off inhaled-aztreonam cycle. Patients performed serial sputum collection, CF-respiratory infection symptom scores (CRISS), and spirometry. Patients achieving a decrease of ≥2 CRISS by day 28 were categorized as subjective responders (SR). The airway microbiome was defined by Illumina MiSeq analysis of the 16S rRNA gene., Results: Thirty-seven patients (median 37.4 years and FEV
1 44% predicted) were enrolled. No significant cohort-wide changes in the microbiome were observed between on/off AZLI cycles in either alpha- or beta-diversity metrics. However, at an individual level shifts were apparent. Twenty-one patients (57%) were SR and fourteen patients did not subjectively respond. While alpha-diversity metrics did not associate with response, patients who did not subjectively respond had a higher abundance of Staphylococcus and Streptococcus, and lower abundance of Haemophilus., Conclusions: The CF microbiome is relatively resilient to AZLI perturbations. However, associated changes were observed at the individual patient level. The relative abundance of key "off-target" organisms associated with subjective improvements suggesting that the microbiome may be used as a tool to predict patient response - potentially improving outcomes., (Copyright © 2019. Published by Elsevier B.V.)- Published
- 2019
- Full Text
- View/download PDF